The Effect of Ligand Exchange and Group Substituent on Biological Activity of Anticancer Ruthenium (III) Complexes (NAMI-A)

The most spread illnesses nowadays and be afraid so far largely in the world are Cancer Diseases because these illnesses represent complicated and tricky to cure. The main methods of new cancer curing is drug therapy. cell killing (cytotoxic) and cell stabilizing (cytostatic) are two wide categories medications used to fight cancer. Many ruthenium based metallodrugs for anticancer diseases has produced as alternates to platinum compounds, the first ruthenium metallodrug enter clinical trials was NAMI-A trans- [tetrachloro (DMSO) (imidazole) ruthenate (III)], this compound explain to have low toxicity and high selectivity against solid tumor metastases when pharmacologically effectiveness doses. In this paper, we describe the building, characterization and designing crystal structure of a novel ruthenium complex, NAMI-A trans- [tetrachloro (DMSO) (imidazole) ruthenate (III)] and its derivative based on density functional theory (DFT) method using Gaussian 03 program Gaussian 2003. The frontier molecular orbital energies HOMO, LUMO, Mulliken charges distribution, complex activity, and stability of the complexes were discussed. The obtained results of building complexes in addition to standard complex are explained that both (C2, C3, C6, C7) are more suitable as anticancer activity compared toward standard complex (C1), while (C4, C5) is lower activity than (C1)